MAPT and early-onset autosomal dominant Alzheimer disease: It is important to emphasize that as a marker of tau pathology, plasma p-tau181 is not intended to be a complete substitution of the A/T/(N) Alzheimer’s disease biomarker framework, which also includes amyloid-β and neurodegeneration biomarkers.